BR112022015628A2 - Vacina de sars-cov-2 - Google Patents

Vacina de sars-cov-2

Info

Publication number
BR112022015628A2
BR112022015628A2 BR112022015628A BR112022015628A BR112022015628A2 BR 112022015628 A2 BR112022015628 A2 BR 112022015628A2 BR 112022015628 A BR112022015628 A BR 112022015628A BR 112022015628 A BR112022015628 A BR 112022015628A BR 112022015628 A2 BR112022015628 A2 BR 112022015628A2
Authority
BR
Brazil
Prior art keywords
cov
sars
vaccine
individual
nucleic acid
Prior art date
Application number
BR112022015628A
Other languages
English (en)
Inventor
Graham Barney
Corbett Kizzmekia
Abiona Olubukola
hutchinson Geoffrey
Mclellan Jason
Wrapp Daniel
Wang Nianshuang
Original Assignee
Us Health
Univ Texas
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Univ Texas, Dartmouth College filed Critical Us Health
Publication of BR112022015628A2 publication Critical patent/BR112022015628A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Trímeros de ectodomínio da S do SARS-CoV-2 estabilizados em uma conformação de pré-fusão, moléculas de ácido nucleico e vetores que codificam essas proteínas e métodos de seu uso e produção são divulgados. Em várias modalidades, os trímeros de ectodomínio da S do SARS-CoV-2 e/ou moléculas de ácido nucleico podem ser utilizados para gerar uma resposta imune à S do SARS-CoV-2 em um indivíduo, por exemplo, uma resposta imune que inibe a infecção por SARS-CoV-2 no indivíduo.
BR112022015628A 2020-02-11 2021-02-11 Vacina de sars-cov-2 BR112022015628A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972886P 2020-02-11 2020-02-11
PCT/US2021/017709 WO2021163365A1 (en) 2020-02-11 2021-02-11 Sars-cov-2 vaccine

Publications (1)

Publication Number Publication Date
BR112022015628A2 true BR112022015628A2 (pt) 2022-09-27

Family

ID=74860458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015628A BR112022015628A2 (pt) 2020-02-11 2021-02-11 Vacina de sars-cov-2

Country Status (11)

Country Link
US (1) US20230113170A1 (pt)
EP (1) EP4103229A1 (pt)
JP (1) JP2023513693A (pt)
KR (1) KR20220140586A (pt)
CN (1) CN115515627A (pt)
AU (1) AU2021221127A1 (pt)
BR (1) BR112022015628A2 (pt)
CA (1) CA3170322A1 (pt)
IL (1) IL295301A (pt)
MX (1) MX2022009836A (pt)
WO (1) WO2021163365A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
GB2594365B (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
CN113527522B (zh) * 2021-09-13 2021-12-21 深圳市瑞吉生物科技有限公司 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗
WO2023047349A1 (en) * 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) * 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
EP4238577A3 (en) 2021-10-22 2023-12-06 BioNTech SE Compositions for administration of different doses of rna
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
US20230167157A1 (en) * 2021-11-29 2023-06-01 Arabian Gulf University ANTIGENIC DETERMINANTS PROTECTIVE IMMUNITY, SERODIAGNOSTIC AND MULTIVALENT SUBUNITS PRECISION VACCINE AGAINST SARS-CoV-2
TW202333780A (zh) 2021-11-29 2023-09-01 德商拜恩技術股份公司 冠狀病毒疫苗
CN114989308B (zh) * 2022-05-12 2023-04-04 中国科学院微生物研究所 新冠病毒嵌合核酸疫苗及其用途
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115287265B (zh) * 2022-07-12 2023-05-23 四川大学华西医院 多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP1425045A4 (en) 2001-09-13 2004-11-10 Genvec Inc ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use

Also Published As

Publication number Publication date
US20230113170A1 (en) 2023-04-13
KR20220140586A (ko) 2022-10-18
CA3170322A1 (en) 2021-08-19
CN115515627A (zh) 2022-12-23
MX2022009836A (es) 2022-11-30
WO2021163365A1 (en) 2021-08-19
AU2021221127A1 (en) 2022-09-22
EP4103229A1 (en) 2022-12-21
IL295301A (en) 2022-10-01
JP2023513693A (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
BR112022015628A2 (pt) Vacina de sars-cov-2
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
BR112022026733A2 (pt) Imunógenos estabilizados de proteína spike (s) de coronavírus e vacinas relacionadas
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
BR112016002614A8 (pt) Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112016007868A2 (pt) vacinas contra o vírus de epstein-barr
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
CY1123403T1 (el) Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
BR112020013236A2 (pt) proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
BR112019004189A2 (pt) trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
AR067830A1 (es) Proteinas streptococcus inmunogenicas
BR112023021654A2 (pt) Vacina contra vírus
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
BR112023003526A2 (pt) Proteínas de fusão de coronavírus imunogênicos e métodos relacionados
BR112022011422A2 (pt) Imunógenos para vírus da caxumba e do sarampo e seus usos
BR112023005674A2 (pt) Construtos anti-cd93 e usos dos mesmos
CL2022003281A1 (es) Inducción de haploides en plantas.
BR112022010680A2 (pt) Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas